IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 71, Issue 9, 2016, Pages 1366-1370

  Freiberger, S N ^a   Zehnder, M ^a   Gafvelin, G ^b   Gronlund H ^b   Kundig T M ^a   Johansen, P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

antibody subclasses; cat allergy; intralymphatic immunotherapy; recombinant allergen

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4; PLACEBO; RECOMBINANT ALLERGEN; RECOMBINANT MAT FELD1 ALLERGEN; TETANUS TOXOID; UNCLASSIFIED DRUG; ALLERGEN; IMMUNOGLOBULIN E; RECOMBINANT PROTEIN;

ALLERGY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CAT; CAT ALLERGY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INJECTION; INTRALYMPHATIC IMMUNOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM; TETANUS; TREATMENT OUTCOME; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES;

ALLERGENS; ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CATS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; RECOMBINANT PROTEINS;

EID: 84978786374     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12946     Document Type: Article

References (27)

1. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J 2015;8:17.
2. Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol 2015;67:171–182.
3. Chudwin DS, Artrip SG, Schiffman G. Immunoglobulin G class and subclass antibodies to pneumococcal capsular polysaccharides. Clin Immunol Immunopathol 1987;44:114–121.
4. Islam D, Wretlind B, Ryd M, Lindberg AA, Christensson B. Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis. Infect Immun 1995;63:2054–2061.
5. Camacho MT, Outschoorn I, Tellez A. Role of immunoglobulin G subclasses in Q fever. Eur J Clin Microbiol Infect Dis 1995;14:1070–1075.
6. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 2001;124:453–460.
7. Raux M, Finkielsztejn L, Salmon-Ceron D, Bouchez H, Excler JL, Dulioust E et al. IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses 2000;16:583–594.
8. Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis 2010;51:e50–e60.
9. Boctor FN, Peter JB. IgG subclasses in human chronic schistosomiasis: over-production of schistosome-specific and non-specific IgG4. Clin Exp Immunol 1990;82:574–578.
10. Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009;150:59–65.
11. Martinez-Gomez JM, Johansen P, Rose H, Steiner M, Senti G, Rhyner C et al. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 2009;64:172–178.
12. Hjalmsdottir A, Wackerle-Men Y, Duda A, Kundig TM, Johansen P. Dosing intervals in intralymphatic immunotherapy. Clin Exp Allergy 2016;46:504–507.
13. Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012;129:1290–1296.
14. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105:17908–17912.
15. Gronlund H, Bergman T, Sandstrom K, Alvelius G, Reininger R, Verdino P et al. Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem 2003;278:40144–40151.
16. Crameri R, Fluckiger S, Daigle I, Kundig T, Rhyner C. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 2007;62:197–206.
17. Zaleska A, Eiwegger T, Soyer O, van de Veen W, Rhyner C, Soyka MB et al. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy 2014;69:1162–1170.
18. Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012;67:217–226.
19. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009;39:469–477.
20. Aalberse R. The role of IgG antibodies in allergy and immunotherapy. Allergy 2011;66(Suppl 95):28–30.
21. Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987;17:459–468.
22. Sanchez-Valverde F, Gil F, Martinez D, Fernandez B, Aznal E, Oscoz M et al. The impact of caesarean delivery and type of feeding on cow's milk allergy in infants and subsequent development of allergic march in childhood. Allergy 2009;64:884–889.
23. Patterson AM, Bonny AE, Shiels WE 2nd, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol 2016;116:168–170.
24. Hylander T, Larsson O, Petersson-Westin U, Eriksson M, Kumlien Georen S, Winqvist O et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res 2016;17:10.
25. Senti G, Iannaccone R, Graf N, Felder M, Tay F, Kundig T. A randomized, double-blind, placebo-controlled study to test the efficacy of topical 2-hydroxypropyl-beta-cyclodextrin in the prophylaxis of recurrent herpes labialis. Dermatology 2013;226:247–252.
26. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol 2013;132:1248–1252.
27. Aalberse RC, Platts-Mills TA. How do we avoid developing allergy: modifications of the TH2 response from a B-cell perspective. J Allergy Clin Immunol 2004;113:983–986.